Clinical Trials Logo

Filter by:
NCT ID: NCT05675098 Not yet recruiting - Cerebral Palsy Clinical Trials

Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy

CP
Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine the effects of Central Nervous System Stimulants, represented by Methylphenidate and Modafinil, compared to placebo control on motor performance in children with Cerebral Palsy. This study will be a triple-masked study per the American Academy of Neurology guidelines for clinical trials.

NCT ID: NCT05649813 Recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region

Start date: November 20, 2022
Phase:
Study type: Observational [Patient Registry]

Primary Objective: - To describe the clinical characteristics of participants with chronic rhinosinusitis with nasal polyps (CRSwNP) in terms of disease severity, Type 2 inflammation-related comorbidities (such as asthma and allergic rhinitis), other associated comorbidities, and treatments used in a real-world setting Secondary Objectives: - Describe the progression in treatment outcomes at different visits (baseline, 3 months, 6 months, and 12 months). - To assess the healthcare resource utilization of participants with CRSwNP in countries of the Gulf region (number of visits, emergency room (ER), surgery, etc).

NCT ID: NCT05618522 Completed - Clinical trials for Acute Chemical Eye Injuries

Omnigen in Acute Chemical Eye Injuries

Omnigen
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

evaluation of the role of Omnigen in acute chemical eye injuries

NCT ID: NCT05390307 Not yet recruiting - Type 1 Diabetes Clinical Trials

Obesity Treatment to Improve Diabetes

OTID
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal transplantation. Innovative medical treatment may help prevent chronic kidney disease (CKD) across our healthcare system. The guideline of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) suggest that patients with obesity, TID/ T2D, and CKD needed either glucagon-like peptide 1 receptor analogs (GLP1-RA) or sodium-glucose cotransport-2 inhibitors (SGLT2i). If neither achieve metabolic control, then the recommendation is to combine both drugs. The evidence base for combining GLP1RA and SGLT2i are not well developed, and hence the impact of the guidelines are limited. This study will provide evidence of discrete metabolic pathways by the GLP1RA/or SGLT2i alone or in combination contributed to metabolic control. The aim of this randomised control trial (RCT) is to test the impact of the combination of GLP1RA/SGLT2i on body weight and kidney damage, in patients with T1DM and CKD. In addition, we will explore associated changes in metabolic pathways with each of the treatments used in the RCT.

NCT ID: NCT05375630 Recruiting - Diabete Type 2 Clinical Trials

Vitamin K2 and Muscle Weakness in Type 2 Diabetes

SARK2
Start date: March 21, 2022
Phase: N/A
Study type: Interventional

The aim of the current study is to determine the effects of vitamin K2 supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.

NCT ID: NCT05317845 Completed - Clinical trials for Diabetes Mellitus, Type 2

An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa

PACT-MEA
Start date: April 21, 2022
Phase:
Study type: Observational

The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases. Participants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor. The study will last for about 6 months.

NCT ID: NCT05239507 Recruiting - Clinical trials for Hepatocellular Carcinoma

OREIOS International Study

OREIOS
Start date: February 1, 2022
Phase:
Study type: Observational

Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care. Based on all these considerations, this multicountry, multicentre, noninterventional, real-world, retrospective study is designed to describe the management patterns, clinical characteristics, possible predictors, and survival outcomes in patients with unresectable HCC. The results of this study might help oncologists in optimal patient selection and sequencing of the systemic therapies.

NCT ID: NCT05238935 Recruiting - Clinical trials for Developmental Dysplasia of the Hip

Do All Patients With Congenital Hip Dysplasia Corrected Operatively Need Physiotherapy

Start date: February 23, 2022
Phase: N/A
Study type: Interventional

Developmental Dysplasia of the Hip (DDH) is a common condition among young children that could range in severity. in most sever cases, surgical intervention is the best choice to correct the hip abnormality with the aim of restoring optimal functional ability. Referring patient for physiotherapy treatment post operative is not a common practice and surgeons relay on children natural developmental milestone in their recovery. however, prescribed physiotherapy treatment could promote maximum functional recovery and wellness. the aim of this research is (1) to evaluate the functional deference between patients who had conventional physiotherapy treatment program and patients who had home program prescribed by the orthopedic surgeon (2) to investigate what might be the underlying risk factors that could enhance or prohibit satisfactory functional level post operatively. all individuals diagnosed with DDH and operated by Dr. Saleh Alsaifi (an orthopedic surgeon at alrazi orthopedic hospital) will be invited to participate in this study. The study will look at the children development in fictional ability postoperatively. not being referred to physiotherapy is a common practice, so the patients in the intervention group will benefit from having regular physiotherapy treatment with no risk at all. the study run from Alrazi orthopedic hospital in kuwait. the research is a collaboration between an orthopedic surgeon (Dr. Saleh Alsaifi) and physiotherapy team and it is expected to recruit all of the eligible patients through 12 months period (approximately 50 patients) then, the data will be sorted for analysis and reporting. the study is not funded with no personal interest.

NCT ID: NCT05214326 Active, not recruiting - Dermatitis Atopic Clinical Trials

A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

AD-impaCT
Start date: January 18, 2022
Phase:
Study type: Observational

Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: - To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. - To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. - Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). - To describe comorbidities related to type 2 inflammation. - To characterize the safety profile of dupilumab in the local Gulf population. - To evaluate treatment satisfaction in the local Gulf population.

NCT ID: NCT05190887 Recruiting - Expectations Clinical Trials

What do Patients Expect After Scaphoid Fractures?

Start date: April 1, 2021
Phase:
Study type: Observational

This study will assess patients expectations pre-op and assess their views on their outcome at one year follow up